JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
复制标题
JAK/STAT作为溶骨性疾病的潜在治疗靶点。
DOI：
10.3390/ijms241210290
复制
发表时间：
2023-06-17
影响因子：
5.6
通讯作者：
Guimaraes-Stabili, Morgana R.
中科院分区：
文献类型：
--
作者：
Godoi, Mariely A.;Camilli, Angelo C.;Gonzales, Karen G. A.;Costa, Vitoria B.;Papathanasiou, Evangelos;Leite, Fabio R. M.;Guimaraes-Stabili, Morgana R.
关键词：
在炎症性疾病中具有主要生物学功能的几种细胞因子通过Janus激酶（JAK）-信号转导子和转录激活子（STAT）信号转导通路发挥作用。JAK使受体的胞质结构域磷酸化，诱导其底物的活化，主要是称为STAT的蛋白质。STAT与这些磷酸化的酪氨酸残基结合，并从细胞质易位到细胞核，进一步调节调节炎症反应的几个基因的转录。JAK/STAT信号通路在炎症性疾病的发病机制中起着关键作用。也有越来越多的证据表明JAK/STAT信号通路的持续激活与几种炎性骨（溶骨性）疾病有关。但具体机制仍有待明确。JAK/STAT信号通路抑制剂已经获得了主要的科学兴趣，以探索其在预防溶骨性疾病中矿化组织破坏方面的潜力。在这里，我们的审查强调了JAK/STAT信号通路在炎症诱导的骨吸收中的重要性，并介绍了JAK抑制剂在溶骨性疾病中的临床研究和实验模型的结果。
Several cytokines with major biological functions in inflammatory diseases exert their functions through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal transduction pathway. JAKs phosphorylate the cytoplasmic domain of the receptor, inducing the activation of its substrates, mainly the proteins known as STATs. STATs bind to these phosphorylated tyrosine residues and translocate from the cytoplasm to the nucleus, further regulating the transcription of several genes that regulate the inflammatory response. The JAK/STAT signaling pathway plays a critical role in the pathogenesis of inflammatory diseases. There is also increasing evidence indicating that the persistent activation of the JAK/STAT signaling pathway is related to several inflammatory bone (osteolytic) diseases. However, the specific mechanism remains to be clarified. JAK/STAT signaling pathway inhibitors have gained major scientific interest to explore their potential in the prevention of the destruction of mineralized tissues in osteolytic diseases. Here, our review highlights the importance of the JAK/STAT signaling pathway in inflammation-induced bone resorption and presents the results of clinical studies and experimental models of JAK inhibitors in osteolytic diseases.
登录
查看更多内容
影响因子：
6.1
作者：
de Aquino, Sabrina Garcia;Manzolli Leite, Fabio Renato;Rossa, Carlos, Jr.
通讯作者：
Rossa, Carlos, Jr.
影响因子：
5.6
作者：
Damerau A;Gaber T;Ohrndorf S;Hoff P
通讯作者：
Hoff P
影响因子：
17.1
作者：
Adam, Susanne;Simon, Nils;Hueber, Axel J.
通讯作者：
Hueber, Axel J.
DOI：
10.1016/j.bbrc.2012.01.074
发表时间：
2012-02-24
影响因子：
3.1
作者：
Barhanpurkar, Amruta P.;Gupta, Navita;Wani, Mohan R.
通讯作者：
Wani, Mohan R.
影响因子：
6.2
作者：
Fleischmann, Roy M.;Huizinga, Tom W. J.;van Vollenhoven, Ronald F.
通讯作者：
van Vollenhoven, Ronald F.